Middle East & Africa Human Vaccine Adjuvants Market Forecast to 2030
Middle East & Africa Human Vaccine Adjuvants Market Forecast to 2030 – Regional Analysis – by Type (Particulate Adjuvant, Emulsion Adjuvant, Combination Adjuvant, and Others), Application (Influenza, Hepatitis, Human papilloma virus (HPV), and Others), and End User (Pharmaceutical and Biotechnology Companies, CMOs and CROs, and Others)
$2,485 – $3,885
- Description
- Toplines
- Reasons for Buying
- Table of Contents
- List of Tables
- LIst of Figures
- List of Companies
- Reviews (0)
Description
Rising prevalence of chronic diseases Bolsters Middle East & Africa Human Vaccine Adjuvants Market
The rising prevalence of chronic diseases is fueling the demand for vaccine adjuvants. Adjuvants are added to vaccines to enhance the efficacy and body’s immune response. They help improve the effectiveness of vaccines by stimulating a stronger and longer-lasting immune response. As the demand for vaccines to prevent and manage chronic diseases continues to grow, the demand for adjuvants also increases. Chronic diseases such as cardiovascular diseases, cancer, diabetes, and respiratory diseases are rising globally. According to the World Health Organization, the most noncommunicable disease-related deaths are cardiovascular diseases, accounting for ~17 million people each year, followed by cancers, chronic respiratory diseases, and diabetes (including deaths associated with the kidney). Furthermore, according to the World Heart Federation, high cholesterol causes 4.4 million deaths yearly, and ?24% of cardiovascular-related deaths are attributable to high low-density lipoprotein (LDL) cholesterol. Thus, the increasing burden of chronic diseases has led to a growing demand for vaccines that can prevent or manage these conditions. The prevalence of hepatitis is also increasing. Adjuvants in hepatitis vaccines aim to elicit robust and durable immunity, particularly in populations with suboptimal responses to standard vaccine formulations, such as those with underlying medical conditions or age-related immune senescence. According to the WHO, more than 350 million people worldwide live with hepatitis B or C. Among all types of hepatitis, several are preventable through vaccination. As per a study by WHO, an estimated 4.5 million premature deaths due to hepatitis could be prevented in low- and middle-income countries by 2030 through vaccination. Thus, the increasing prevalence of chronic diseases drives the growth of the Middle East & Africa human vaccine adjuvants market.
Middle East & Africa Human Vaccine Adjuvants Market Overview
Saudi Arabia has planned to localize 40% of the pharmaceutical sector and reduce its import dependence as part of its National Transformation Program. In Saudi Arabia, economic and social changes have led to a shift in sedentary lifestyles, leading to an increasing prevalence of obesity and a projected rise in metabolic syndrome. Furthermore, a lack of disease awareness and knowledge about disease transmission among patients has increased the prevalence of infectious diseases in the country. For instance, according to a study, “Hepatitis B virus infection in Saudi Arabia and the UAE: Public health challenges and their remedial measures,” published in PubMed in 2023, Saudi Arabia faces critical challenges in Hepatitis B virus treatment and management even after implementing a mass vaccination program. Similarly, according to a report by ICO/IARC Information Centre on HPV and Cancer in 2023, Saudi Arabia has a population of 10.7 million women aged 15 years and older who are at risk of developing HPV-related cervical cancer. Thus, the increasing prevalence of infectious diseases in the UAE fuels the demand for human vaccine adjuvants. In recent years, the Kingdom of Saudi Arabia has invested substantially in the healthcare and pharmaceutical sectors, aiming to enhance domestic production, research, and development capabilities. This strategic focus has set the stage for potential growth, influencing the Middle East & Africa human vaccine adjuvants market. In Saudi Arabia, the King Fahd Medical City, King Faisal Specialist Hospital & Research Centre, and the Ministry of Health are among the institutions actively involved in advancing healthcare research, including those related to vaccines and adjuvants. Such investment in research facilities and medical infrastructure signals a commitment to contributing to the global vaccine landscape. It is also projected to pave the way for adjuvant research and development advancements.
Middle East & Africa Human Vaccine Adjuvants Market Revenue and Forecast to 2030 (US$ Million)
Middle East & Africa Human Vaccine Adjuvants Market Segmentation
The Middle East & Africa human vaccine adjuvants market is categorized into type, application, end user, and country.
Based on type, the Middle East & Africa human vaccine adjuvants market is segmented particulate adjuvant, emulsion adjuvant, combination adjuvant, and others. The particulate adjuvant segment held the largest market share in 2022.
In terms of application, the Middle East & Africa human vaccine adjuvants market is categorized into influenza, hepatitis, human papilloma virus (HPV), and others. The influenza segment held the largest market share in 2022.
By end user, the Middle East & Africa human vaccine adjuvants market is segmented into pharmaceutical and biotechnology companies, CMOs and CROs, and others. The pharmaceutical and biotechnology companies segment held the largest market share in 2022.
By country, the Middle East & Africa human vaccine adjuvants market is segmented into Saudi Arabia, South Africa, the UAE, and the Rest of Middle East & Africa. Saudi Arabia dominated the Middle East & Africa human vaccine adjuvants market share in 2022.
Novartis AG, CSL Ltd, Seppic SA, Croda International Plc, Novavax Inc, and Phibro Animal Health Corp are some of the leading companies operating in the Middle East & Africa human vaccine adjuvants market.
Summary Info
| Industry: | |
|---|---|
| Pricing options: | |
| Geographical coverage: | |
| Year of Publication: |
According to the Research Team’ research, the Middle East & Africa human vaccine adjuvants market was valued at US$ 49.18 million in 2022 and is expected to reach US$ 119.37 million by 2030, registering a CAGR of 11.7% from 2022 to 2030. Rising trend of personalized vaccines and rising prevalence of chronic diseases are among the critical factors attributed to drive the Middle East & Africa human vaccine adjuvants market growth.
Precision or personalized vaccines are a growing trend in the Middle East & Africa human vaccine adjuvants market. These vaccines target specific genetic or molecular characteristics of a patient’s disease, assisting the production of vaccines tailored to each patient’s unique immune response. The technique can potentially improve vaccination efficacy and safety, leading to increased interest in personalized vaccines for treating diseases such as cancer, infectious diseases, and autoimmune disorders.
Adjuvants that can boost the immune response to these tailored vaccines are required to produce personalized vaccines. Adjuvants are essential in stimulating the immune system to develop a targeted and powerful response to the vaccine’s specific antigens. As a result, there is an increasing demand for adjuvants that can effectively boost immune responses to personalized vaccines. In recent years, there has been a strong emphasis on R&D efforts to identify and create adjuvants that can effectively increase the immune response to personalized vaccines. For instance, in December 2022, Moderna and Merck announced mRNA-4157/V940, an investigational personalized mRNA cancer vaccine, in combination with KEYTRUDA(R) (pembrolizumab). Adjuvant treatment with mRNA-4157/V940 in combination with KEYTRUDA reduced the risk of recurrence or death by 44% compared with KEYTRUDA alone. Regulatory bodies and healthcare organizations recognize personalized vaccines’ potential for enhancing public health outcomes. Thus, adjuvants that effectively improve the immune response to personalized vaccinations are increasingly being developed, enhancing vaccine efficacy and safety. This trend drives substantial innovation and investment in the Middle East & Africa human vaccine adjuvants market.
On the contrary, manufacturing complexities and regulatory challenges hampers the growth of Middle East & Africa human vaccine adjuvants market.
Based on type, the Middle East & Africa human vaccine adjuvants market is segmented particulate adjuvant, emulsion adjuvant, combination adjuvant, and others. The particulate adjuvant segment held 39.2% market share in 2022, amassing US$ 19.26 million. It is projected to garner US$ 46.11 million by 2030 to register 11.5% CAGR during 2022-2030.
In terms of application, the Middle East & Africa human vaccine adjuvants market is categorized into influenza, hepatitis, human papilloma virus (HPV), and others. The influenza segment held 37.7% share of Middle East & Africa human vaccine adjuvants market in 2022, amassing US$ 18.55 million. It is anticipated to garner US$ 46.60 million by 2030 to expand at 12.2% CAGR during 2022-2030.
By end user, the Middle East & Africa human vaccine adjuvants market is segmented into pharmaceutical and biotechnology companies, CMOs and CROs, and others. The pharmaceutical and biotechnology companies segment held 48.9% share of Middle East & Africa human vaccine adjuvants market in 2022, amassing US$ 24.06 million. It is projected to garner US$ 60.44 million by 2030 to expand at 12.2% CAGR from 2022 to 2030.
By country, the Middle East & Africa human vaccine adjuvants market is segmented into Saudi Arabia, South Africa, the UAE, and the Rest of Middle East & Africa. Our regional analysis states that Saudi Arabia captured 29.4% share of Middle East & Africa human vaccine adjuvants market in 2022. It was assessed at US$ 15.15 million in 2022 and is likely to hit US$ 38.96 million by 2030, registering a CAGR of 12.5% during 2022-2030.
Key players operating in the Middle East & Africa human vaccine adjuvants market are Novartis AG, CSL Ltd, Seppic SA, Croda International Plc, Novavax Inc, and Phibro Animal Health Corp, among others.
o Highlights key business priorities in order to assist companies to realign their business strategies.
o The key findings and recommendations highlight crucial progressive industry trends in the Middle East & Africa human vaccine adjuvants market, thereby allowing players across the value chain to develop effective long-term strategies.
o Develop/modify business expansion plans by using substantial growth offering developed and emerging markets.
o Scrutinize in-depth Middle East & Africa market trends and outlook coupled with the factors driving the Middle East & Africa human vaccine adjuvants market, as well as those hindering it
o Enhance the decision-making process by understanding the strategies that underpin commercial interest with respect to client products, segmentation, pricing, and distribution.
1. Introduction
1.1 The the Reporting Teams Research Report Guidance
1.2 Market Segmentation
2. Executive Summary
2.1 Key Insights
3. Research Methodology
3.1 Coverage
3.2 Secondary Research
3.3 Primary Research
4. Middle East & Africa Human Vaccine Adjuvants Market – Key Market Dynamics
4.1 Middle East & Africa Human Vaccine Adjuvants Market – Key Market Dynamics
4.2 Market Drivers
4.2.1 Rising Prevalence of Chronic Diseases
4.2.2 Growing Focus on Immunization Programs
4.3 Market Restraints
4.3.1 Manufacturing Complexities and Regulatory Challenges
4.4 Market Opportunities
4.4.1 Growing Pharmaceutical Industry
4.5 Future Trends
4.5.1 Rising Trend of Personalized Vaccines
4.6 Impact of Drivers and Restraints:
5. Human Vaccine Adjuvants Market – Middle East & Africa Market Analysis
5.1 Middle East & Africa Human Vaccine Adjuvants Market Revenue (US$ Million), 2020 – 2030
5.2 Middle East & Africa Human Vaccine Adjuvants Market Forecast Analysis
6. Middle East & Africa Human Vaccine Adjuvants Market Analysis – by Type
6.1 Particulate Adjuvant
6.1.1 Overview
6.1.2 Particulate Adjuvant: Middle East & Africa Human Vaccine Adjuvants Market – Revenue and Forecast to 2030 (US$ Million)
6.2 Emulsion Adjuvant
6.2.1 Overview
6.2.2 Emulsion Adjuvant: Middle East & Africa Human Vaccine Adjuvants Market – Revenue and Forecast to 2030 (US$ Million)
6.3 Combination Adjuvant
6.3.1 Overview
6.3.2 Combination Adjuvant: Middle East & Africa Human Vaccine Adjuvants Market – Revenue and Forecast to 2030 (US$ Million)
6.4 Others
6.4.1 Overview
6.4.2 Others: Middle East & Africa Human Vaccine Adjuvants Market – Revenue and Forecast to 2030 (US$ Million)
7. Middle East & Africa Human Vaccine Adjuvants Market Analysis – by Application
7.1 Influenza
7.1.1 Overview
7.1.2 Influenza: Middle East & Africa Human Vaccine Adjuvants Market – Revenue and Forecast to 2030 (US$ Million)
7.2 Hepatitis
7.2.1 Overview
7.2.2 Hepatitis: Middle East & Africa Human Vaccine Adjuvants Market – Revenue and Forecast to 2030 (US$ Million)
7.3 Human papilloma virus (HPV)
7.3.1 Overview
7.3.2 Human Papilloma Virus (HPV): Middle East & Africa Human Vaccine Adjuvants Market – Revenue and Forecast to 2030 (US$ Million)
7.4 Others
7.4.1 Overview
7.4.2 Others: Middle East & Africa Human Vaccine Adjuvants Market – Revenue and Forecast to 2030 (US$ Million)
8. Middle East & Africa Human Vaccine Adjuvants Market Analysis – by End User
8.1 Pharmaceutical and Biotechnology Companies
8.1.1 Overview
8.1.2 Pharmaceutical and Biotechnology Companies: Middle East & Africa Human Vaccine Adjuvants Market – Revenue and Forecast to 2030 (US$ Million)
8.2 CMOs and CROs
8.2.1 Overview
8.2.2 CMOs and CROs: Middle East & Africa Human Vaccine Adjuvants Market – Revenue and Forecast to 2030 (US$ Million)
8.3 Others
8.3.1 Overview
8.3.2 Others: Middle East & Africa Human Vaccine Adjuvants Market – Revenue and Forecast to 2030 (US$ Million)
9. Middle East & Africa Human Vaccine Adjuvants Market – Country Analysis
9.1 Middle East & Africa
9.1.1 Middle East & Africa Human Vaccine Adjuvants Market Breakdown, by Key Countries, 2022 and 2030 (%)
9.1.1.1 Saudi Arabia Human Vaccine Adjuvants Market – Revenue and Forecast to 2030 (US$ Million)
9.1.1.1.1 Saudi Arabia Human Vaccine Adjuvants Market Breakdown, by Type
9.1.1.1.2 Saudi Arabia Human Vaccine Adjuvants Market Breakdown, by Application
9.1.1.1.3 Saudi Arabia Human Vaccine Adjuvants Market Breakdown, by End User
9.1.1.2 South Africa Human Vaccine Adjuvants Market – Revenue and Forecast to 2030 (US$ Million)
9.1.1.2.1 South Africa Human Vaccine Adjuvants Market Breakdown, by Type
9.1.1.2.2 South Africa Human Vaccine Adjuvants Market Breakdown, by Application
9.1.1.2.3 South Africa Human Vaccine Adjuvants Market Breakdown, by End User
9.1.1.3 United Arab Emirates Human Vaccine Adjuvants Market – Revenue and Forecast to 2030 (US$ Million)
9.1.1.3.1 United Arab Emirates Human Vaccine Adjuvants Market Breakdown, by Type
9.1.1.3.2 United Arab Emirates Human Vaccine Adjuvants Market Breakdown, by Application
9.1.1.3.3 United Arab Emirates Human Vaccine Adjuvants Market Breakdown, by End User
9.1.1.4 Rest of Middle East & Africa Human Vaccine Adjuvants Market – Revenue and Forecast to 2030 (US$ Million)
9.1.1.4.1 Rest of Middle East & Africa Human Vaccine Adjuvants Market Breakdown, by Type
9.1.1.4.2 Rest of Middle East & Africa Human Vaccine Adjuvants Market Breakdown, by Application
9.1.1.4.3 Rest of Middle East & Africa Human Vaccine Adjuvants Market Breakdown, by End User
10. Industry Landscape
10.1 Overview
11. Company Profiles
11.1 Novartis AG
11.1.1 Key Facts
11.1.2 Business Description
11.1.3 Products and Services
11.1.4 Financial Overview
11.1.5 SWOT Analysis
11.1.6 Key Developments
11.2 CSL Ltd
11.2.1 Key Facts
11.2.2 Business Description
11.2.3 Products and Services
11.2.4 Financial Overview
11.2.5 SWOT Analysis
11.2.6 Key Developments
11.3 Seppic SA
11.3.1 Key Facts
11.3.2 Business Description
11.3.3 Products and Services
11.3.4 Financial Overview
11.3.5 SWOT Analysis
11.3.6 Key Developments
11.4 Croda International Plc
11.4.1 Key Facts
11.4.2 Business Description
11.4.3 Products and Services
11.4.4 Financial Overview
11.4.5 SWOT Analysis
11.4.6 Key Developments
11.5 Novavax Inc
11.5.1 Key Facts
11.5.2 Business Description
11.5.3 Products and Services
11.5.4 Financial Overview
11.5.5 SWOT Analysis
11.5.6 Key Developments
11.6 Phibro Animal Health Corp
11.6.1 Key Facts
11.6.2 Business Description
11.6.3 Products and Services
11.6.4 Financial Overview
11.6.5 SWOT Analysis
11.6.6 Key Developments
12. Appendix
12.1 About The the Reporting Teams
12.2 Glossary of Terms
Table 1. Middle East & Africa Human Vaccine Adjuvants Market Segmentation
Table 2. Middle East & Africa Human Vaccine Adjuvants Market – Revenue and Forecast to 2030 (US$ Million)
Table 3. Middle East & Africa Human Vaccine Adjuvants Market – Revenue and Forecast to 2030 (US$ Million) – by Type
Table 4. Middle East & Africa Human Vaccine Adjuvants Market – Revenue and Forecast to 2030 (US$ Million) – by Application
Table 5. Middle East & Africa Human Vaccine Adjuvants Market – Revenue and Forecast to 2030 (US$ Million) – by End User
Table 6. Saudi Arabia Human Vaccine Adjuvants Market – Revenue and Forecast to 2030(US$ Million) – by Type
Table 7. Saudi Arabia Human Vaccine Adjuvants Market – Revenue and Forecast to 2030(US$ Million) – by Application
Table 8. Saudi Arabia Human Vaccine Adjuvants Market – Revenue and Forecast to 2030(US$ Million) – by End User
Table 9. South Africa Human Vaccine Adjuvants Market – Revenue and Forecast to 2030(US$ Million) – by Type
Table 10. South Africa Human Vaccine Adjuvants Market – Revenue and Forecast to 2030(US$ Million) – by Application
Table 11. South Africa Human Vaccine Adjuvants Market – Revenue and Forecast to 2030(US$ Million) – by End User
Table 12. United Arab Emirates Human Vaccine Adjuvants Market – Revenue and Forecast to 2030(US$ Million) – by Type
Table 13. United Arab Emirates Human Vaccine Adjuvants Market – Revenue and Forecast to 2030(US$ Million) – by Application
Table 14. United Arab Emirates Human Vaccine Adjuvants Market – Revenue and Forecast to 2030(US$ Million) – by End User
Table 15. Rest of Middle East & Africa Human Vaccine Adjuvants Market – Revenue and Forecast to 2030(US$ Million) – by Type
Table 16. Rest of Middle East & Africa Human Vaccine Adjuvants Market – Revenue and Forecast to 2030(US$ Million) – by Application
Table 17. Rest of Middle East & Africa Human Vaccine Adjuvants Market – Revenue and Forecast to 2030(US$ Million) – by End User
Table 18. Recent Growth Strategies in the Human Vaccine Adjuvants Market
Table 19. Glossary of Terms, Human Vaccine Adjuvants Market
Figure 1. Middle East & Africa Human Vaccine Adjuvants Market Segmentation, by Country
Figure 2. Impact Analysis of Drivers and Restraints
Figure 3. Middle East & Africa Human Vaccine Adjuvants Market Revenue (US$ Million), 2022 – 2030
Figure 4. Middle East & Africa Human Vaccine Adjuvants Market Share (%) – by Type (2022 and 2030)
Figure 5. Particulate Adjuvant: Middle East & Africa Human Vaccine Adjuvants Market – Revenue and Forecast to 2030 (US$ Million)
Figure 6. Emulsion Adjuvant: Middle East & Africa Human Vaccine Adjuvants Market – Revenue and Forecast to 2030 (US$ Million)
Figure 7. Combination Adjuvant: Middle East & Africa Human Vaccine Adjuvants Market – Revenue and Forecast to 2030 (US$ Million)
Figure 8. Others: Middle East & Africa Human Vaccine Adjuvants Market – Revenue and Forecast to 2030 (US$ Million)
Figure 9. Middle East & Africa Human Vaccine Adjuvants Market Share (%) – by Application (2022 and 2030)
Figure 10. Influenza: Middle East & Africa Human Vaccine Adjuvants Market – Revenue and Forecast to 2030 (US$ Million)
Figure 11. Hepatitis: Middle East & Africa Human Vaccine Adjuvants Market – Revenue and Forecast to 2030 (US$ Million)
Figure 12. Human papilloma virus (HPV): Middle East & Africa Human Vaccine Adjuvants Market – Revenue and Forecast to 2030 (US$ Million)
Figure 13. Others: Middle East & Africa Human Vaccine Adjuvants Market – Revenue and Forecast to 2030 (US$ Million)
Figure 14. Middle East & Africa Human Vaccine Adjuvants Market Share (%) – by End User (2022 and 2030)
Figure 15. Pharmaceutical and Biotechnology Companies: Middle East & Africa Human Vaccine Adjuvants Market – Revenue and Forecast to 2030 (US$ Million)
Figure 16. CMOs and CROs: Middle East & Africa Human Vaccine Adjuvants Market – Revenue and Forecast to 2030 (US$ Million)
Figure 17. Others: Middle East & Africa Human Vaccine Adjuvants Market – Revenue and Forecast to 2030 (US$ Million)
Figure 18. Middle East & Africa Human Vaccine Adjuvants Market Breakdown, by Key Countries – Revenue (2022) (US$ Million)
Figure 19. Middle East & Africa Human Vaccine Adjuvants Market Breakdown, by Key Countries, 2022 and 2030 (%)
Figure 20. Saudi Arabia Human Vaccine Adjuvants Market – Revenue and Forecast to 2030(US$ Million)
Figure 21. South Africa Human Vaccine Adjuvants Market – Revenue and Forecast to 2030(US$ Million)
Figure 22. United Arab Emirates Human Vaccine Adjuvants Market – Revenue and Forecast to 2030(US$ Million)
Figure 23. Rest of Middle East & Africa Human Vaccine Adjuvants Market – Revenue and Forecast to 2030(US$ Million)
The List of Companies – Middle East & Africa Human Vaccine Adjuvants Market
1. Novartis AG
2. CSL Ltd
3. Seppic SA
4. Croda International Plc
5. Novavax Inc
6. Phibro Animal Health Corp
You must be logged in to post a review.
Reviews
There are no reviews yet.